Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

4,373

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions
Diabetes Mellitus
Interventions
DRUG

Pioglitazone

Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.

DRUG

Placebo

Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months

Trial Locations (19)

Unknown

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Multiple Cities

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Takeda

INDUSTRY